The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
- 2020-10-28
- RCT
- Nutrients 12(11)
- Mariangela Rondanelli
- Antonella Riva
- Giovanna Petrangolini
- Pietro Allegrini
- Luisa Bernardinelli
- Teresa Fazia
- Gabriella Peroni
- Clara Gasparri
- Mara Nichetti
- Milena Anna Faliva
- Maurizio Naso
- Simone Perna
- PubMed: 33126534
- DOI: 10.3390/nu12113298
- High evidence
- Rigorous Journal
- Clinical
statistically significant interactions between time and group were observed for the primary endpoint glycemia (β = 0.36, p < 0.0001) and for the secondary endpoints HDL (β = -0.10, p < 0.0001), total cholesterol/HDL (β = 0.27, p < 0.0001), LDL (β = 0.15, p = 0.005), LDL/HDL (β = 0.23, p = 0.001), insulin (β = 1.28, p = 0.04), glycated hemoglobin (β = 0.21, p = 0.0002), A1c-derived average glucose (β = 0.34, p = 0.0002), ApoB (β = 6.00, p = 0.01), ApoA (β = -4.50, p = 0.04), ApoB/ApoA (β = 0.08, p = 0.003), waist circumference (β = 1.89, p = 0.05), VATβ = 222.37, p = 0.005)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes